Research Projects

The study aims to identify a novel therapeutic compound that can reduce prostate cancer (PCa) without affecting off-target cells. In silico studies have shown that 4-HO-2-oxo-1, 2-dihydro-quinoline-3-carboxylic acid (2-carbamoyl-phenyl)-amide (D2) can limit PCa cell proliferation by inhibiting hypoxia by down-regulating hypoxia-inducible factor (HIF) 1? and ? interactions. D2 was less toxic to noncancerous cell lines and may alter the level of other proteins involved in PCa progression and metastasis. In vivo studies will investigate the molecular mechanism of D2 inhibiting PCa cell growth. The study will be conducted on xenograft nude mice models of PCa, using immunohistochemistry, western blot, antiangiogenic activity, and flow cytometry to understand the mechanism of action. The study will help identify a novel therapeutic compound that can suppress castration-resistant prostate cancer progression by altering the tumor microenvironment. D2 shows better efficacy and superior bioavailability than conventional anti-prostate cancer drugs, making it suitable for terminally ill patients. The study also helps understand the molecular mechanism behind metastatic prostate cancer progression and prevention, potentially helping chemo-resistant metastatic PCa patients recover with minimal side effects.